Sourcing Peptides from China: What US Sellers Need to Know

By Peptide Ecommerce · August 10, 2026

For a US seller sourcing peptides from China, import documentation, regulatory obligations, and lot records are central responsibilities. Questions about suitability for a particular use belong with qualified researchers and regulators. Your import file connects the product, manufacturer, intended use, and shipment information for review by CBP and FDA.

This article covers what is different about Chinese-origin peptides from a documentation and seller-regulatory-exposure standpoint. A separate article in this series covers the general supplier vetting process. The present article covers what that general process does not: the GMP documentation differences specific to Chinese manufacturers, the COA content to review for Chinese-origin peptides and how FDA evaluates intended use, the import documentation requirements for commercial sellers, and what due diligence looks like for Chinese origin specifically.

Key Facts

China ended separate drug GMP certification on December 1, 2019 (NMPA).
Chinese Drug Manufacturing Certificates identify the manufacturing site and authorized manufacturing scope (NMPA).
FDA's Q7 guidance permits an appropriately characterized in-house primary reference standard when an official standard is unavailable (FDA).
Import Alert 66-41 addresses unapproved new drugs promoted in the US (FDA).
FDA evaluates intended use through communications, product characteristics, and distribution circumstances (Cornell Legal Information Institute, federal regulatory text).

TL;DR

A product review brings together analytical results, methods, and agreed acceptance limits (FDA).
Customs entry records describe the merchandise, its value, origin, and tariff classification (Cornell Legal Information Institute, federal regulatory text).
FDA reviews imported drugs for applicable registration, listing, application, labeling, and manufacturing requirements (FDA).

Chinese manufacturers in the peptide supply chain

China's manufacturing presence combines supplier networks, production capacity, and cost advantages documented in the broader API industry (FDA, testimony of Janet Woodcock). FDA's 2019 testimony identified lower utility costs and established raw-material networks in China. In its 2025 results, WuXi AppTec, the vendor, states that its total solid phase peptide synthesizer reactor volume exceeded 100,000 liters following expansion at Taixing.

US buyers have international sourcing options: Bachem, the vendor, states that its Vista facility in California manufactures commercial APIs, peptide new chemical entities, and intermediates (Bachem). For a Chinese supplier, the practical documentation review concerns the manufacturer's identity, licensed activities where applicable, and the records covering your product.

GMP certification: what Chinese certification means for a US seller

China ended separate drug GMP certification on December 1, 2019, while retaining required manufacturing inspections (NMPA). The relevant Chinese body is the National Medical Products Administration (NMPA), which replaced the China Food and Drug Administration in 2018. Current due diligence examines manufacturing authorization and inspection evidence. US finished pharmaceutical manufacturing falls under 21 CFR Part 211, while FDA's Q7 guidance addresses API manufacturing.

This matters for US sellers because Chinese manufacturing authorization and inspection follow NMPA requirements, while US GMP requirements are set separately under 21 CFR Part 211 for finished pharmaceuticals and FDA's Q7 guidance for APIs.

Two review points are worth examining.

First, the scope review concerns the current Drug Manufacturing Certificate for a Chinese drug manufacturer (NMPA). This authorization identifies the manufacturing site and permitted manufacturing scope. Your supplier's product and process records connect the peptide being purchased to those authorized activities, and the certificate's validity details identify its current term.

Second, inspection review concerns the authority, date, scope, findings, and corrective actions of each inspection. China's required on-site inspections continued after separate GMP certification ended. FDA announced expanded unannounced foreign inspections in 2025, building on its China and India pilot. FDA evaluates imported drugs against applicable US requirements, including current good manufacturing practices.

For a Chinese drug manufacturer, your review file includes its current Drug Manufacturing Certificate, manufacturing scope, validity dates, and available inspection records (NMPA). Third-party audit reports identify the standard assessed, activities examined, findings, and corrective actions. Those details support a product-specific review of the supplier's quality system.

COA content and intended use for Chinese-origin peptides

The Certificate of Analysis (COA) is the document that travels with a peptide shipment and records the testing performed on that lot (FDA). Relevant tests follow the product's specifications and customer requirements. HPLC purity, appearance, moisture, and identity information can form part of that record when relevant to the material and its agreed specification.

For US buyers, COA completeness is assessed against the tests, acceptance limits, and results relevant to the product.

The first issue is the intended use statement. Under 21 CFR 201.128, the FDA evaluates a product's intended use based on the totality of evidence available, including labeling, promotional materials, the seller's website, and customer communications (Cornell Legal Information Institute, federal regulatory text). The supplier's documentation is part of that evidence. FDA also considers product design or composition and distribution circumstances.

For a US operator selling research-use-only (RUO) compounds, website text, catalog descriptions, marketing emails, and customer communications contribute to the evidence of intended use (FDA). FDA has cited peptide sellers' website and social media claims when identifying products marketed as drugs.

The second issue is analytical methods. FDA's API guidance recommends COAs identifying tests, acceptance limits, and results. China's drug GMP rules also address specifications and testing procedures. A method citation or controlled method identifier, supported by validation records where applicable, helps your laboratory assess how each reported result was obtained.

The third issue is reference standard traceability. FDA's Q7 guidance allows an appropriately established in-house primary reference standard when an officially recognized standard is unavailable. The laboratory documents its identity, purity, source, storage, and use. Secondary standards are qualified against a primary standard, and the analytical method determines the relevant reference materials (FDA).

Your supplier documentation file combines the lot COA, test methods, acceptance criteria, relevant reference-standard records, and intended-use communications. An agreed COA specification makes your documentation expectations explicit. Statements about intended use can appear in labeling and other written communications linked to the product and transaction.

US import documentation requirements for commercial sellers

Commercial peptide imports involve customs entry requirements and the FDA requirements applicable to the product and intended use (FDA). Import-alert screening and the distinction between commercial and personal shipments are additional parts of that review. Related guide: FDA Import Alert 66-40: Check a Peptide Supplier.

The first issue is FDA import-alert screening. Import Alert 66-41 addresses unapproved new drugs promoted in the US and guides FDA personnel on detention of identified products from listed firms (FDA). A US importer receiving a shipment detained under an import alert has the burden of demonstrating that the shipment is compliant before it will be released. The response addresses the stated violation with relevant product, labeling, authorization, and shipment evidence.

The second is CBP entry requirements. Commercial imports require accurate Harmonized Tariff Schedule classification, proper invoicing that accurately describes the product, and for FDA-regulated products, advance notice under the FDA Prior Notice program if the product is classified as a food or dietary supplement. The customs entry identifies the product, value, origin, and tariff classification (Cornell Legal Information Institute, federal regulatory text). FDA entry review also uses manufacturer, importer, product-description, and intended-use information.

The third issue is the distinction between personal and commercial importation. Under FDA's personal importation policy, agency personnel may exercise enforcement discretion in some circumstances for an individual's own use (FDA). Imports for resale are commercial transactions and follow the applicable customs and FDA entry requirements, including for small shipments.

Objective-intent exposure under 21 CFR 201.128

FDA evaluates objective intent through labeling and communications, product design or composition, and the circumstances surrounding distribution (Cornell Legal Information Institute, federal regulatory text). Your commercial practices and product presentation therefore form part of the evidence alongside written records.

21 CFR 201.128 defines intended use as determined by the totality of evidence, including the product's labeling, promotional materials, and any other communications by the seller about the product's use (Cornell Legal Information Institute, federal regulatory text). This means that the FDA does not need to find an explicit drug claim in a COA or label to conclude that a product is being marketed as a drug. Evidence of intended use can come from the seller's website, testimonials published or endorsed by the seller, social media posts, or statements made in customer communications.

For a US seller sourcing from China, product descriptions, advertising, customer communications, and distribution practices contribute to FDA's intended-use assessment. FDA has evaluated peptide sellers' marketing across websites and social media when identifying drug-marketing violations.

Your product file connects each lot with its COA, testing records, original manufacturer, transaction documents, and relevant intended-use communications. Your website and catalog accurately describe the uses for which you offer the product. FDA evaluates those communications together with the product and the circumstances of its distribution.

What China-specific due diligence looks like

General supplier vetting checklists cover the mechanics of COA verification, lab accreditation, sample-to-lot chain confirmation, and legal entity mapping. This section covers what is different for Chinese-origin peptides specifically.

First, China-specific verification covers the manufacturer's current authorization and the regulatory records applicable to the material. For Chinese drug manufacturers, the Drug Manufacturing Certificate records site and manufacturing scope. Chemical APIs use the AEP registration platform for associated review and approval (NMPA). The relevant registration and review records document the material's standing within that Chinese framework.

Second, intended-use documentation can include a statement on the COA and separately retained written communications. A statement on the COA travels with that lot record (Cornell Legal Information Institute, federal regulatory text). A supplier email identified by product, lot, order, and shipment can be retained with the same transaction file.

Third, prior FDA detention review combines the supplier's written history with the relevant FDA import-alert records. Chinese manufacturers that have shipped to US buyers before may have prior FDA detention history. A written inquiry can identify affected products, facilities, dates, and the status of any corrective action.

For a complete documentation framework for peptide supplier evaluation, including the vetting checklist that covers all origin types, see /30-peptides.html.

Frequently Asked Questions

How long is a Chinese Drug Manufacturing Certificate valid?

NMPA's manufacturing provisions set a five-year term for the Drug Manufacturing Certificate. The certificate identifies its issuing authority, manufacturing site, scope, and validity details.

What information helps identify the manufacturer behind a repackaged API?

FDA's Q7 guidance recommends retaining the original manufacturer's identity, batch number, and authentic COA. For your shipment, those details connect the supplied material to its original production record.

Which additional records apply when the imported material is an API?

Imported APIs are subject to foreign establishment registration, drug listing and labeling requirements. The applicable requirements follow the product's intended use and the conditions of its importation.

How does FDA compare a drug shipment with its registration records?

FDA compares the declared manufacturer and product with its registration and listing databases. It also checks the declared importer or consignee against the foreign manufacturer's registration information.

Sources

Considering outside help? Questions to ask before choosing a peptide business coach